ABOUT US
Emerald Corporate Group is a consultancy providing expertise in health economics, health technology assessments, pricing and reimbursement strategy and event management services to assist healthcare companies to achieve successful market access for their medical technologies.
We are a healthcare value strategy consultancy that brings medical therapies and technologies to market with energy. We help our clients define, develop and create value in today’s complex healthcare environments.
We have a proven track record of success.
Since our inception, we have developed price, access, and value strategies for a variety of new product launches and the enhancement of in-market products.
We have an innovative approach.
From our extensive engagements with corporate and government clients, coupled with our own in depth industry experience, we have developed numerous innovative methods and tools to deliver robust solutions for our clients.
We have extensive healthcare industry experience.
Our team’s background in the pharmaceutical industry combined with our deep global understanding of healthcare markets helps us arrive at the most appropriate and individualized solutions for our clients.
We have expertise in a wide range of therapeutic areas.
Our therapeutic experience spans a broad spectrum of areas such as neurology, cardiovascular, immunology and oncology and includes specialist expertise in several orphan drug diseases.
We have macro and micro global connections.
Our international relationships are what set us apart. We have worked and are currently working in markets across North America, Europe, Asia and the Pacific region.
Our Founder and Director
George Papadopoulos
BSc (Hons), GradDipEpi, MAICD
George has more than 25 years of experience in the medical technology and pharmaceutical industries including clinical research, health economics, reimbursement, pricing, and business development. He has worked at both local and international levels at senior levels in Australia, Belgium and the United States including Pharmacia, Johnson & Johnson, Schering-Plough and Merck.
George established Emerald Corporate Group and has since assisted multiple healthcare companies to successfully gain market access for innovative technologies.
George is expert in developing health economic and reimbursement strategies, strategic pricing initiatives, early assessment of commercial opportunities and preparation of health economic submissions to reimbursement authorities.
George received his BSc [Hons] from the University of Sydney and Grad Dip Epi (Pharmacoepi) from the University of Newcastle. He is a current member of ISPOR and the current Treasurer of ISPOR Australia. He held the position of President of ARCS (Australasian Society of Regulatory and Clinical Scientists) and was a Board Member for five years from 2015 and is currently proud to be an active member of ARCS, HTAi (Health Technology Assessment International), iHEA (International Health Economics Association) and a member of the AICD (Australian Institute of Company Directors).
Connect with George on LinkedIn 
Emerald Corporate Group is a consultancy providing expertise in health economics, health technology assessments, pricing and reimbursement strategy and event management services.